All In Biotech

Drug Trial Radar · NCT04362813

Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia

Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Canakinumab on Cytokine Release Syndrome in Patients With COVID-19-induced Pneumonia (CAN-COVID)

Last checked: Nov 20, 2026Latest source record: Jan 24, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 454 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

454

Actual

Start

Apr 30, 2020

Primary completion

Sep 16, 2020

Study completion Dec 22, 2020

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of canakinumab plus standard-of-care (SOC) compared with placebo plus SOC in patients with COVID-19-induced pneumonia and cytokine release syndrome (CRS).

Conditions

  • Cytokine Release Syndrome (CRS) in Patients With COVID-19-induced Pneumonia

Interventions

  • CanakinumabDrug

    Canakinumab 450 mg for body weight 40-\<60 kg, 600 mg for 60-80 kg or 750 mg for \>80 kg in 250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.

  • PlaceboDrug

    250 mL of 5% dextrose infused IV over 2 hours. Single dose on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants Who Survived Without Requiring Invasive Mechanical Ventilation From Day 3 to Day 29, Primary AnalysisTime frame: Day 3 to Day 29

Locations

39 sites in 6 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Birmingham, Alabama

  • Novartis Investigative Site

    Glendale, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    San Francisco, California

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Boston, Massachusetts

  • Novartis Investigative Site

    Brooklyn, New York

  • Novartis Investigative Site

    Chapel Hill, North Carolina

  • Novartis Investigative Site

    Cleveland, Ohio

  • Novartis Investigative Site

    Philadelphia, Pennsylvania

  • Novartis Investigative Site

    Houston, Texas

  • Novartis Investigative Site

    Richmond, Virginia

  • Novartis Investigative Site

    Tacoma, Washington

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Bergamo, BG, Italy

  • Novartis Investigative Site

    Cona, FE, Italy

  • Novartis Investigative Site

    Barnaul, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Moscow, Russia

  • Novartis Investigative Site

    Ryazan, Russia

  • Novartis Investigative Site

    S-Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Saint Petersburg, Russia

  • Novartis Investigative Site

    Sestroretsk, Russia

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    Madrid, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    San Sebastián de los Reyes, Madrid, Spain

  • Novartis Investigative Site

    Barnet, United Kingdom

  • Novartis Investigative Site

    Coventry, United Kingdom

  • Novartis Investigative Site

    Leeds, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.